Candriam S.C.A. Bicycle Therapeutics PLC Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Candriam S.C.A. holds 1,050,598 shares of BCYC stock, worth $15.3 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

1,050,598

Previous 759,180 38.39%

Holding current value

$15.3 Million

Previous $15.4 Million 55.07%

% of portfolio

0.14%

Previous 0.09%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$19.58 - $27.24 $5.71 Million - $7.94 Million	291,418 Added 38.39%	1,050,598 $23.8 Million
Q2 2024 Aug 05, 2024	SELL	$20.02 - $24.69 $2.6 Million - $3.21 Million	-130,078 Reduced 14.63%	759,180 $15.4 Million
Q1 2024 May 03, 2024	BUY	$16.75 - $26.1 $335,000 - $522,000	20,000 Added 2.3%	889,258 $22.1 Million
Q4 2023 Feb 14, 2024	SELL	$13.29 - $22.2 $5.1 Million - $8.52 Million	-384,003 Reduced 30.64%	869,258 $15.7 Million
Q3 2023 Nov 13, 2023	SELL	$19.9 - $26.25 $398,000 - $525,000	-20,000 Reduced 1.57%	1,253,261 $25.2 Million
Q2 2023 Aug 08, 2023	SELL	$18.95 - $28.67 $567,552 - $858,666	-29,950 Reduced 2.3%	1,273,261 $32.5 Million
Q1 2023 May 12, 2023	BUY	$20.02 - $31.37 $2.56 Million - $4.02 Million	128,000 Added 10.89%	1,303,211 $27.7 Million
Q4 2022 Feb 13, 2023	SELL	$20.37 - $32.9 $1.16 Million - $1.88 Million	-57,043 Reduced 4.63%	1,175,211 $34.8 Million
Q3 2022 Nov 10, 2022	BUY	$17.49 - $28.44 $6.95 Million - $11.3 Million	397,578 Added 47.63%	1,232,254 $28.7 Million
Q2 2022 Aug 03, 2022	BUY	$12.95 - $46.99 $10.8 Million - $39.2 Million	834,676 New	834,676 $14 Million

Others Institutions Holding BCYC

# of Institutions

111

Shares Held

40.8M

Call Options Held

39.6K

Put Options Held

24.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $431M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account